Clinical study for external washing by traditional Chinese medicine in the treatment of multiple infectious wounds of diabetic foot: Study protocol clinical trial (SPIRIT compliant).
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
26
4
2020
pubmed:
26
4
2020
medline:
10
5
2020
Statut:
ppublish
Résumé
Diabetic foot (DF) is among the most serious complications of type 2 diabetes. DF infection (DFI) is a key factor in the deterioration and development of DF, so controlling infection plays an important role in the treatment of the disease. Traditional Chinese medicine foot bath has been widely used in China as a complementary and alternative therapy to improve circulation and infection control of DF. However, the existing evidence shows that its efficacy and safety are still insufficient. We report a study protocol about a multicenter, double-blind, randomized, placebo controlled trial which aims to make well-designed clinical trials to evaluate the efficacy and safety of herbal medicine foot bath decoction (FBD) and explore the mechanism of external washing of Chinese herbs in DFI. This study is a multicenter, double-blind, randomized, placebo controlled clinical trial in which 60 eligible participants were randomly divided into an experimental group and control group at a 1:2 ratio. Both groups received the same basic treatment for DF disease, the experimental group used FBD and ordinary dressing changes, while half of the patients in the control group received placebo and ordinary dressings, and the other half received placebo and silver ion dressings. Patients in both groups will be evaluated weekly for efficacy during the intervention. The primary efficacy indicators include the types of wound pathogens, interleukin 6 and tumor necrosis factor α. Secondary efficacy indicators included blood glucose, blood lipids, wound area, lower extremity blood vessel diameter, blood flow speed, walking speed, walking distance, and traditional Chinese medicine syndrome scores. We will also conduct a safety evaluation of the drug at the end of the trial. This multicenter, double-blind, randomized, placebo clinical trial not only provides data on the efficacy and safety of FBD, but also provides a novel treatment strategy for clinicians and DF patients.
Sections du résumé
BACKGROUND
BACKGROUND
Diabetic foot (DF) is among the most serious complications of type 2 diabetes. DF infection (DFI) is a key factor in the deterioration and development of DF, so controlling infection plays an important role in the treatment of the disease. Traditional Chinese medicine foot bath has been widely used in China as a complementary and alternative therapy to improve circulation and infection control of DF. However, the existing evidence shows that its efficacy and safety are still insufficient. We report a study protocol about a multicenter, double-blind, randomized, placebo controlled trial which aims to make well-designed clinical trials to evaluate the efficacy and safety of herbal medicine foot bath decoction (FBD) and explore the mechanism of external washing of Chinese herbs in DFI.
METHODS
METHODS
This study is a multicenter, double-blind, randomized, placebo controlled clinical trial in which 60 eligible participants were randomly divided into an experimental group and control group at a 1:2 ratio. Both groups received the same basic treatment for DF disease, the experimental group used FBD and ordinary dressing changes, while half of the patients in the control group received placebo and ordinary dressings, and the other half received placebo and silver ion dressings. Patients in both groups will be evaluated weekly for efficacy during the intervention. The primary efficacy indicators include the types of wound pathogens, interleukin 6 and tumor necrosis factor α. Secondary efficacy indicators included blood glucose, blood lipids, wound area, lower extremity blood vessel diameter, blood flow speed, walking speed, walking distance, and traditional Chinese medicine syndrome scores. We will also conduct a safety evaluation of the drug at the end of the trial.
DISCUSSION
CONCLUSIONS
This multicenter, double-blind, randomized, placebo clinical trial not only provides data on the efficacy and safety of FBD, but also provides a novel treatment strategy for clinicians and DF patients.
Identifiants
pubmed: 32332634
doi: 10.1097/MD.0000000000019841
pii: 00005792-202004240-00045
pmc: PMC7220697
doi:
Substances chimiques
Drugs, Chinese Herbal
0
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e19841Références
Ann Intern Med. 1992 Jul 15;117(2):97-105
pubmed: 1605439
Diabet Med. 2018 May;35(5):541-547
pubmed: 29443421
J Sci Food Agric. 2018 Jul;98(9):3551-3562
pubmed: 29315599
Diabetes Metab Res Rev. 2000 Sep-Oct;16 Suppl 1:S75-83
pubmed: 11054894
Int J Low Extrem Wounds. 2014 Mar;13(1):17-21
pubmed: 24659623
JAMA. 2005 Jan 12;293(2):217-28
pubmed: 15644549
Chin Med. 2015 Jul 02;10:16
pubmed: 26161134
Diabet Med. 1998 Jul;15(7):539-53
pubmed: 9686693
Evid Based Complement Alternat Med. 2014;2014:985176
pubmed: 24696703
Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3276
pubmed: 31958217
Wound Repair Regen. 2016 Jan-Feb;24(1):112-26
pubmed: 26663430
Diabetes Metab Res Rev. 2020 Feb;36(2):e3218
pubmed: 31659861
BMC Endocr Disord. 2016 Jul 07;16(1):38
pubmed: 27388440
Am Fam Physician. 1998 Mar 15;57(6):1325-32, 1337-8
pubmed: 9531915
Int J Low Extrem Wounds. 2015 Mar;14(1):19-27
pubmed: 25573978
J Vasc Surg. 2016 Feb;63(2 Suppl):3S-21S
pubmed: 26804367
Diabetes Metab. 2008 Apr;34(2):87-95
pubmed: 18242114
J Intern Med. 1994 May;235(5):463-71
pubmed: 8182403
Int J Clin Pract. 2017 Oct;71(10):
pubmed: 28892282
Expert Opin Pharmacother. 2015 Apr;16(6):821-32
pubmed: 25736920
Diabetes Metab Res Rev. 2012 Feb;28 Suppl 1:225-31
pubmed: 22271742
Diabetologia. 2007 Jan;50(1):18-25
pubmed: 17093942
Expert Opin Drug Metab Toxicol. 2013 Jan;9(1):51-61
pubmed: 22998215
Diabetes Metab Syndr. 2017 Apr - Jun;11(2):149-156
pubmed: 27377687